Well, that's an interesting point you raise, because, as I mentioned on Monday, a lot of other countries have struggled with the prices for these new, very promising, life-changing cystic fibrosis drugs. There was a stalemate in many of these countries between the reimbursement body and the company because they wouldn't bring their price down. Some of the patient groups in the U.K. and Switzerland, for example, decided that they were going to switch strategies and seek out a compulsory licence and obtain a generic version of those drugs from a South American country. It was only when that threat was made that you started to see progress made at the negotiation table.
I think that's something for patient groups to consider, not just with respect to this particular product line and this company, but more generally. It doesn't make sense to me that a company that saw its second quarter results go up 62% most recently and made $2 billion selling four cystic fibrosis drugs is not in the hot seat to the same extent as the government because it refuses to bring out product to us unless we pay among the highest prices in the world. It just doesn't seem sensible to me.